It is well documented that higher FGF23 levels are associated with increased arterial stiffness, total body atherosclerosis, left ventricular hypertrophy, and consequently, there is an increased risk cardiovascular mortality, even in patients without renal insufficiency. This evidence concerns the gene FGF23 and left ventricular hypertrophy.